10 Best Long-Term Dividend Stocks to Buy According to Billionaires

5. Johnson & Johnson (NYSE:JNJ)

Number of Billionaire Holders: 18

Johnson & Johnson (NYSE:JNJ) is an American multinational healthcare company that specializes in pharmaceuticals, biotechnology, and medical technologies. The company recently announced its Q1 2025 earnings, reporting revenue of $21.9 billion, a 2.4% increase compared to the same quarter last year. Revenue also surpassed analysts’ expectations by $315.6 million. Net earnings came in at $11 billion, representing a 238% year-over-year surge.

Throughout the quarter, Johnson & Johnson (NYSE:JNJ) further cemented its standing as an innovation leader by advancing several projects in its development pipeline. Highlights included progress with TREMFYA for inflammatory bowel disease, the combination of RYBREVANT and LAZCLUZE for non-small-cell lung cancer, and developments with OTTAVA, its robotic soft tissue surgery system. The company also expanded its neuroscience portfolio with the acquisition of Intra-Cellular Therapies.

Johnson & Johnson (NYSE:JNJ) continued to show financial strength, posting free cash flow of $3.4 billion for the quarter, up from $2.8 billion a year earlier. On April 15, it announced a 4.8% increase in its quarterly dividend to $1.30 per share, marking its 63rd consecutive year of dividend growth. With a dividend yield of 3.36% as of April 27, JNJ is one of the best dividend stocks according to billionaires.

At the end of Q4 2024, 18 billionaires held positions in Johnson & Johnson (NYSE:JNJ), worth over $2.9 billion collectively. With over 8.1 million shares in JNJ, Ken Fisher’s Fisher Asset Management was the company’s leading stakeholder in Q4.